Martien Kas

Last updated
Martien Kas
Born (1966-11-27) 27 November 1966 (age 57)
EducationPh.D. in Behavioral Neuroscience, Stanford University/University of Groningen
Known forTranslational and transdiagnostic neuroscience research
AwardsMarie Curie Fellowship, VIDI grant, Innovative Medicine Initiative
Scientific career
Fields Behavioural Neuroscience
Institutions University of Groningen, Groningen, Netherlands

Martien J. H. Kas (born 27 November 1966, Uithoorn) is professor at the Groningen Institute for Evolutionary Life Sciences, University of Groningen, the Netherlands, where he leads a research group entitled "Behavioural Neuroscience". His research aims to develop a quantitative, transdiagnostic and translational neurobiological approach to the understanding of neuropsychiatric disorders in order to accelerate the discovery and development of better treatments for patients with those disorders. The ability to precisely link neuropsychiatric symptoms to underlying neurobiology will not only facilitate the development of better treatments, it will also allow physicians to provide patients with a better understanding of the complexities and management of their illness.

Contents

He is currently President of the European College of Neuropsychopharmacology (ECNP), the largest European organisation for neuroscience applied research. ECNP provides a platform for interactions between scientists, patients and their families, pharmaceutical industry and regulators for optimizing the treatment of brain disorders, and organizes many activities, including an annual congress with 4500-6000 participants.

Career

Kas received his M.Sc. in biology, with specialization in neurobiology, psychopharmacology, and ethology from the Vrije Universiteit Amsterdam, and a Ph.D. in behavioral neuroscience from Stanford University and the University of Groningen. He completed a postdoctoral fellowship at the University Medical Center Utrecht and was a visiting scientist at the Social, Genetic and Developmental Psychiatry Research Centre at the Institute of Psychiatry (London). He was an associate professor in the Department of Translational Neuroscience, Brain Center Rudolf Magnus, at the University Medical Center Utrecht

By applying interspecies genetic analysis of neurobehavioral traits (in mice and humans), Kas' research aims to identify functional genotypephenotype relationships relevant to the development and etiology-directed treatment of brain disorders, such as schizophrenia and autism spectrum disorders.

Honors

Kas has received a Marie Curie Fellowship as principal investigator. He received a VIDI grant as principal investigator on a project studying interspecies genetics of neurobehavioral traits in mice and men. As project coordinator he was awarded the Innovative Medicines Initiative PRISM1 and PRISM2 projects, and co-awarded the Innovative Medicines Initiative projects for Translational Endpoints in Autism (EU-AIMS) and Aims-2-trials.

Publications

Kas has published extensively, with numerous peer-reviewed articles and book chapters to his name.

Related Research Articles

David Gil Amaral is a professor of psychiatry at the University of California, Davis, United States, and since 1998 has been the research director at the M.I.N.D. Institute, an affiliate of UC Davis, engaged in interdisciplinary research into the causes and treatment of autism and related neurodevelopmental disorders. Amaral joined the UC Davis faculty as a professor in the Department of Psychiatry and the Center for Neuroscience and as an investigator at the California Regional Primate Research Center in 1991. Since 1995, he has been a professor of psychiatry in the UC Davis School of Medicine, with an appointment to the Center for Neuroscience.

<span class="mw-page-title-main">Institute of Psychiatry, Psychology and Neuroscience</span> Research institution in London, England

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) is a leading centre for mental health and neuroscience research, education and training in Europe. It is dedicated to understanding, preventing and treating mental illness, neurological conditions, and other conditions that affect the brain. The IoPPN is a faculty of King's College London, England, and was previously known as the Institute of Psychiatry (IoP).

Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychology factors. Within neuropsychiatry, the mind is considered "as an emergent property of the brain", whereas other behavioral and neurological specialties might consider the two as separate entities. Those disciplines are typically practiced separately.

Psychiatric genetics is a subfield of behavioral neurogenetics and behavioral genetics which studies the role of genetics in the development of mental disorders. The basic principle behind psychiatric genetics is that genetic polymorphisms are part of the causation of psychiatric disorders.

Rs6265, also called Val66Met or G196A, is a gene variation, a single nucleotide polymorphism (SNP) in the BDNF gene that codes for brain-derived neurotrophic factor.

Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He is also an Emeritus Senior Investigator at the National Institute for Health and Care Research (NIHR) and has been on the advisory boards of numerous research councils. He was President of the European College of Neuropsychopharmacology from 2013 to 2016.

<span class="mw-page-title-main">Neurogenomics</span>

Neurogenomics is the study of how the genome of an organism influences the development and function of its nervous system. This field intends to unite functional genomics and neurobiology in order to understand the nervous system as a whole from a genomic perspective.

The Semel Institute for Neuroscience and Human Behavior is a research institute of the University of California Los Angeles (UCLA). It includes a number of centers, including the "Center for Neurobehavioral Genetics", which uses DNA sequencing, gene expression studies, bioinformatics, and the genetic manipulation of model organisms to understand brain and behavioral phenotypes.

Geraldine Dawson is an American child clinical psychologist, specializing in autism. She has conducted research on early detection, brain development, and treatment of autism spectrum disorders (ASD) and collaborated on studies of genetic risk factors in autism. Dawson is William Cleland Distinguished Professor of Psychiatry and Behavioral Sciences and professor of psychology and neuroscience, former director, Duke Institute for Brain Sciences and founding director of the Duke Center for Autism and Brain Development at Duke University Medical Center. Dawson was president of the International Society for Autism Research, a scientific and professional organization devoted to advancing knowledge about autism spectrum disorders. From 2008 to 2013, Dawson was research professor of psychiatry at the University of North Carolina at Chapel Hill and was chief science officer for Autism Speaks. Dawson also held the position of adjunct professor of psychiatry at Columbia University and is professor emerita of psychology at University of Washington. She is a fellow of the American Psychological Society, American Psychological Association, International Society for Autism Research, and the Society of Clinical Child and Adolescent Psychology.

Autism spectrum disorder (ASD) refers to a variety of conditions typically identified by challenges with social skills, communication, speech, and repetitive sensory-motor behaviors. The 11th International Classification of Diseases (ICD-11), released in January 2021, characterizes ASD by the associated deficits in the ability to initiate and sustain two-way social communication and restricted or repetitive behavior unusual for the individual's age or situation. Although linked with early childhood, the symptoms can appear later as well. Symptoms can be detected before the age of two and experienced practitioners can give a reliable diagnosis by that age. However, official diagnosis may not occur until much older, even well into adulthood. There is a large degree of variation in how much support a person with ASD needs in day-to-day life. This can be classified by a further diagnosis of ASD level 1, level 2, or level 3. Of these, ASD level 3 describes people requiring very substantial support and who experience more severe symptoms. ASD-related deficits in nonverbal and verbal social skills can result in impediments in personal, family, social, educational, and occupational situations. This disorder tends to have a strong correlation with genetics along with other factors. More research is identifying ways in which epigenetics is linked to autism. Epigenetics generally refers to the ways in which chromatin structure is altered to affect gene expression. Mechanisms such as cytosine regulation and post-translational modifications of histones. Of the 215 genes contributing, to some extent in ASD, 42 have been found to be involved in epigenetic modification of gene expression. Some examples of ASD signs are specific or repeated behaviors, enhanced sensitivity to materials, being upset by changes in routine, appearing to show reduced interest in others, avoiding eye contact and limitations in social situations, as well as verbal communication. When social interaction becomes more important, some whose condition might have been overlooked suffer social and other exclusion and are more likely to have coexisting mental and physical conditions. Long-term problems include difficulties in daily living such as managing schedules, hypersensitivities, initiating and sustaining relationships, and maintaining jobs.

<span class="mw-page-title-main">Research Domain Criteria</span> Diagnostic framework in personalized psychiatry

The Research Domain Criteria (RDoC) project is an initiative of personalized medicine in psychiatry developed by US National Institute of Mental Health (NIMH). In contrast to the Diagnostic and Statistical Manual of Mental Disorders (DSM) maintained by the American Psychiatric Association (APA), RDoC aims to address the heterogeneity in the current nosology by providing a biologically-based, rather than symptom-based, framework for understanding mental disorders. "RDoC is an attempt to create a new kind of taxonomy for mental disorders by bringing the power of modern research approaches in genetics, neuroscience, and behavioral science to the problem of mental illness."

Dup15q syndrome is the common name for maternally inherited chromosome 15q11.2-q13.1 duplication syndrome. This is a genomic copy number variant that leads to a type of neurodevelopmental disorder, caused by partial duplication of the proximal long arm of Chromosome 15. This variant confers a strong risk for autism spectrum disorder, epilepsy, and intellectual disability. It is the most common genetic cause of autism, accounting for approximately 1-3% of cases. Dup15q syndrome includes both interstitial duplications and isodicentric duplications of 15q11.2-13.1.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

The development of an animal model of autism is one approach researchers use to study potential causes of autism. Given the complexity of autism and its etiology, researchers often focus only on single features of autism when using animal models.

Wim van den Brink is emeritus Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He was Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.

Elisabeth Binder is a medical doctor and neuroscientist specializing in the study of mood and anxiety disorders. She is the director of the Department of Translational Research of the Max Planck Institute of Psychiatry in Munich, Germany. In addition to research, she is a member of the executive committee of the European College of Neuropsychopharmacology (ECNP).

Charles L. Raison is an American psychiatrist and professor of psychiatry at the University of Wisconsin-Madison School of Medicine and Public Health as well as the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families and Professor with the School of Human Ecology in Madison, Wisconsin.

<span class="mw-page-title-main">Haim Belmaker</span> Israeli professor of psychiatry

Prof. Robert Haim Belmaker, is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Hoffer-Vickar Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel until his retirement and is now Emeritus.

Joseph Thomas Coyle Jr. is an American psychiatrist and neuroscientist. He is the Eben S. Draper Professor of Psychiatry and Neuroscience at Harvard Medical School.

Christopher J. Pittenger is an American psychiatrist and translational neuroscientist. He is a professor of psychiatry at the Yale School of Medicine and Director of the Yale OCD Research Clinic.

References